Marksans Pharma Ltd. — Investor Relations & Filings
Marksans Pharma Ltd. specializes in the research, development, and large-scale manufacturing of generic formulations. The company’s therapeutic focus spans pain management, cardiovascular health, central nervous system disorders, anti-diabetics, and gastrointestinal treatments. Its product portfolio includes diverse delivery systems such as solid orals, soft gelatin capsules, and liquid formulations, serving both the over-the-counter and prescription markets. The organization operates advanced manufacturing facilities compliant with international regulatory standards, facilitating a robust supply chain across major global markets including North America, Europe, and Australia. By integrating comprehensive research and development with efficient production processes, the company provides a broad range of high-quality, cost-effective medicinal products to a global patient base.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | |
| Press Release | 2026-04-01 | English | |
| Trading Window | 2026-03-26 | English | |
| Copy of Newspaper Publication | 2026-03-12 | English | |
| General Updates | 2026-03-11 | English | |
| General Updates | 2026-03-10 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42169802 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | ||
| 42178891 | Press Release | 2026-04-01 | English | ||
| 42170668 | Trading Window | 2026-03-26 | English | ||
| 42166032 | Copy of Newspaper Publication | 2026-03-12 | English | ||
| 42171933 | General Updates | 2026-03-11 | English | ||
| 42178511 | General Updates | 2026-03-10 | English | ||
| 42183952 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-12 | English | ||
| 42280686 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-06 | English | ||
| 42280898 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-06 | English | ||
| 42286059 | Copy of Newspaper Publication | 2026-02-06 | English | ||
| 42181842 | Press Release | 2026-02-05 | English | ||
| 42182307 | Investor Presentation | 2026-02-05 | English | ||
| 42183229 | Outcome of Board Meeting | 2026-02-05 | English | ||
| 42208443 | General Updates | 2026-01-27 | English | ||
| 42167857 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-01-22 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
Marksans Pharma Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/62142/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=62142 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=62142 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=62142 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 62142}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Marksans Pharma Ltd. (id: 62142)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.